<a href="https://www.fiercebiotech.com/biotech/aptose-facing-cash-crunch-exits-blood-cancer-pact-after-hanmi-buyout-blocks-development" hreflang="en">Aptose, facing cash crunch, exits blood cancer pact after Hanmi buyout blocks development</a>
fiercebiotech.com·May 14, 2026
Aptose Biosciences has abandoned a deal for a blood cancer drug candidate amid its upcoming acquisition by Hanmi Pharmaceutical.
Aptose Biosciences' decision to scrap a blood cancer drug candidate deal amid its takeover by Hanmi Pharmaceutical underscores the importance of strategic pivots in biotech mergers and acquisitions. For someone tracking biotech investments, this highlights the need to closely monitor such corporate actions, as they can significantly impact the development pipeline and future valuation of biotech companies.